ライフサイエンスコーパス: therapeutic agent

1 ne (PIP) is an alkaloid which is potent as a therapeutic agent.

2 nges associated with developing this type of therapeutic agent.

3 D inhibitor to be developed as an anticancer therapeutic agent.

4 sts that glibenclamide may be an appropriate therapeutic agent.

5 y and that can be further developed as a new therapeutic agent.

6 ple studies to master its potential use as a therapeutic agent.

7 ial factors that impact its development as a therapeutic agent.

8 atural blue colorant, fluorescent marker and therapeutic agent.

9 , a selective ASK1 inhibitor, as a potential therapeutic agent.

10 utralizes NiV, indicating its potential as a therapeutic agent.

11 factor and development of it as a potential therapeutic agent.

12 visualization of the biodistribution of the therapeutic agent.

13 r clinical use can still only carry a single therapeutic agent.

14 ptidase IV (DPP-4) which limits their use as therapeutic agents.

15 raction (HFpEF) justify the search for novel therapeutic agents.

16 es and for the development of more effective therapeutic agents.

17 e infectious disease therapy using available therapeutic agents.

18 ed analogues of diltiazem and tiazesim, both therapeutic agents.

19 ated with sensitivity/resistance of multiple therapeutic agents.

20 patients to one of several genotype-matched therapeutic agents.

21 assays and have a low likelihood of becoming therapeutic agents.

22 have poor cell permeability, limiting use as therapeutic agents.

23 ctivity relationships (SARs) for prospective therapeutic agents.

24 many natural extracellular stimuli and many therapeutic agents.

25 ls could be harnessed for the development of therapeutic agents.

26 relate with protection and have potential as therapeutic agents.

27 linical relevance, targeting strategies, and therapeutic agents.

28 ment of SARS-CoV-2 vaccines and immune-based therapeutic agents.

29 -ups are presented for better utilization as therapeutic agents.

30 isms and a broader utility for PARP-targeted therapeutic agents.

31 mprove the yield of HSCs for stem cell-based therapeutic agents.

32 and can improve the efficacy of conventional therapeutic agents.

33 of local growth, metastasis, and response to therapeutic agents.

34 derstand disease pathogenesis and test novel therapeutic agents.

35 both the absence and presence of (targeted) therapeutic agents.

36 may represent a promising group of antisense therapeutic agents.

37 otein (HDL) mimics have emerged as promising therapeutic agents.

38 cial defense system that protects cells from therapeutic agents.

39 their ability to develop resistance against therapeutic agents.

40 es are considered to have great potential as therapeutic agents.

41 bs) hold great promise as research tools and therapeutic agents.

42 erous topical, oral, and injectable targeted therapeutic agents.

43 tential lead molecules for development of AD therapeutic agents.

44 g starting points for the development of new therapeutic agents.

45 ighly selective melatonin tool compounds and therapeutic agents.

46 ing more and more an issue of novel targeted therapeutic agents.

47 this will yield a potent and broad class of therapeutic agents.

48 potential in the delivery of a wide range of therapeutic agents.

49 rrier to progress for this emerging class of therapeutic agents.

50 Neutralizing antibodies have potential as therapeutic agents.

51 , there are currently no effective anti-DENV therapeutic agents.

52 ay serve to examine the effects of candidate therapeutic agents.

53 terization of the effectiveness of candidate therapeutic agents.

54 nd may guide the development of vaccines and therapeutic agents.

55 3-trifluoromethyl coumarins and analogues of therapeutic agents.

56 idity and mortality, urgently requires novel therapeutic agents.

57 system for the development of diagnostic and therapeutic agents.

58 enotype against a variety of chemo/targeting therapeutic agents.

59 le chemical probes and potential anti-cancer therapeutic agents.

60 stitute novel targets for the development of therapeutic agents.

61 rs of the innate immune system and promising therapeutic agents.

62 erve as lead compounds for development of AD therapeutic agents.

63 the development of new biochemical tools and therapeutic agents.

64 the action of countless natural stimuli and therapeutic agents.

65 rgeting or promoting select cytokines as new therapeutic agents.

66 tion, and toxicities of metabolites of these therapeutic agents.

67 will facilitate the development of improved therapeutic agents.

68 19 to accelerate the testing of vaccines and therapeutic agents.

69 livery systems as sophisticated carriers for therapeutic agents.

70 drug developers pursuing histology-agnostic therapeutic agents.

71 ial properties, and are considered potential therapeutic agents.

72 ountered in bioactive compounds and approved therapeutic agents.

73 f particular interest as orally administered therapeutic agents.

74 ic agents with Gd to enhance the efficacy of therapeutic agents.

75 g an efficient barrier for the absorption of therapeutic agents.

76 uture studies and incorporate testing of new therapeutic agents.

77 order to develop more precise and effective therapeutic agents.

78 ndalone therapy or in conjunction with other therapeutic agents.

79 ivery of molecules, nanoparticles, and other therapeutic agents.

80 ddictive, highlighting the need for improved therapeutic agents.

81 kill the tumor cells, making them efficient therapeutic agents.

82 t of preclinical and clinical studies of new therapeutic agents.

83 -rhPSMA-7.3 in comparison to the established therapeutic agent (177)Lu-PSMA I&T (imaging and therapy)

84 being explored for enhancing the delivery of therapeutic agents across the filtration barrier of the

85 protein degradation are a major new class of therapeutic agents, active in a number of hematologic ma

86 Analysis of independent studies with salvage therapeutic agents affirmed RD3 loss in surviving resist

87 hat hydroxychloroquine could be an effective therapeutic agent against Covid-19.

88 ore the potential of CapsidCas13a(s) as both therapeutic agents against antimicrobial-resistant bacte

89 ibitors of SARS-CoV-2 and provides potential therapeutic agents against COVID-19.

90 some native peptides have great potential as therapeutic agents against intestinal inflammation, pote

91 s a blueprint for developing next-generation therapeutic agents against LOAD.

92 for cancer therapy, and thus the search for therapeutic agents against LOX has been widely sought.

93 dn remain viable leads as topical preventive/therapeutic agents against the global threat of multidru

94 for HD clinical trials, particularly if the therapeutic agent aims to reduce CAG repeat instability.

95 ts identify dinaciclib as a novel and potent therapeutic agent alone or in combination with gemcitabi

96 ial drug chloroquine (CQ) has been used as a therapeutic agent, alone or in combination, to treat aut

97 heranostics that are composed of imaging and therapeutic agents already approved.

98 tors as potential biological antagonists and therapeutic agents, although few catalytic inhibitors in

99 The therapeutic agent and diagnostic probe were integrated i

100 B extract has the potential to be a valuable therapeutic agent and may serve to establish a strategy

101 een widely investigated for their utility as therapeutic agents and as tools for in vitro negative se

102 ncapsulation and release of various types of therapeutic agents and biological effectors are highligh

103 provides opportunities for the discovery of therapeutic agents and biomarkers in the setting of hepa

104 on of thermoresponsive hydrogels loaded with therapeutic agents and cells are receiving much attentio

105 hould guide adequate prioritization of those therapeutic agents and combination strategies which are

106 tionality in designing nanomaterials as self-therapeutic agents and delivery vehicles for antimicrobi

107 nanostructure, enhancing active targeting of therapeutic agents and facilitating new combination ther

108 astes and utilization of their bioactives as therapeutic agents and in functional food industry.

109 to potential applications in developing new therapeutic agents and materials.

110 roteins are critical components of influenza therapeutic agents and may provide alternative strategie

111 t and testing of approved histology-agnostic therapeutic agents and present data on other agents curr

112 A challenge to the design of improved therapeutic agents and prevention strategies for neuroin

113 g delivery because of their ability to carry therapeutic agents and readily functionalized surfaces.

114 d metastasis, and ii) preclinically identify therapeutic agents and screen anticancer drugs.

115 ings open new avenues for the development of therapeutic agents and synthetic biology.

116 factin and Herbmedotcin were selected as the therapeutic agents and the hydrogels were formulated bas

117 ibitors of the MCU are valuable as potential therapeutic agents and tools to study mitochondrial Ca(2

118 RS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current

119 50 000 deaths, there is a desperate need for therapeutic agents and vaccines.

120 acted much interest as a source of potential therapeutic agents, and in particular as alternatives to

121 a)/oxidized phospholipids, describe emerging therapeutic agents, and propose clinical trial designs t

122 ean research and development spending on new therapeutic agents approved by the FDA, capitalized at a

123 Data were analyzed on new therapeutic agents approved by the US Food and Drug Admi

124 BBBO as well as extravasation of IA injected therapeutic agents are essential to develop strategies a

125 Novel biomarkers and therapeutic agents are needed to avoid the otherwise ine

126 ging forth an era in which more than a dozen therapeutic agents are now available to treat patients.

127 Additionally, as new therapeutic agents are tested and post-approval data bec

128 is an ideal antigenic target for a universal therapeutic agent, as it is highly conserved across infl

129 nteractions (PPIs) holds great potential for therapeutic agents, as illustrated by the successful dru

130 smart platform for delivering and producing therapeutic agents, as monotherapy or in combination wit

131 may become a basis for the discovery of new therapeutic agents, as well as advance the diagnostic fi

132 of multispecific drugs: those that enrich a therapeutic agent at a particular site of action and tho

133 tration apparatus presents a barrier against therapeutic agents based on charge and/or molecular size

134 te of research and development costs for new therapeutic agents based on publicly available data.

135 of this recruitment with clinically relevant therapeutic agents blocks metastasis.

136 radiotracers for PET will help in developing therapeutic agents by providing an imaging tool for asse

137 light future directions for developing novel therapeutic agents by targeting MSTFs.

138 cal timeline for approval of a new antiviral therapeutic agent can exceed 10 years.

139 y, we demonstrate that oligonucleotide-based therapeutic agents can be delivered to oligodendrocytes

140 Thus, the ill effect of JQ1 or its derived therapeutic agents cannot be ignored during cancer treat

141 specifically, apoptosis and necrosis, during therapeutic agent characterizations.

142 Importantly, there are no therapeutic agents currently in use that can alter the c

143 cancers, and despite decades of research, no therapeutic agent directly targeting RAS has been clinic

144 itors may have potential as cardioprotective therapeutic agents during cancer chemotherapy.

145 However, to date, no single therapeutic agent exerts its effects via perturbing hete

146 toxicity of amyloid proteins-as a potential therapeutic agent for ALS.

147 e conclude that CO may represent a promising therapeutic agent for APAP-induced liver injury.

148 ghlight the potential of ATRAM as a specific therapeutic agent for diseases that lead to acidic tissu

149 We conclude that SM-164 is a promising therapeutic agent for early stage bone and lung metastas

150 ollistatin-based fusion protein - as a novel therapeutic agent for focal or asymmetric myopathies.

151 ccelerate the development of an immune-based therapeutic agent for HIV cure.

152 r results position enasidenib as a promising therapeutic agent for improvement of anemia and provide

153 s offers the potential for a highly specific therapeutic agent for MG.

154 ASN002 might be an effective novel therapeutic agent for moderate-to-severe AD.

155 thromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease

156 endogenous amino acid, offers new hope as a therapeutic agent for refractory TLE.

157 undance of neutralization IgG is a promising therapeutic agent for rescuing COVID-19 patients in the

158 e data suggest that CIP may serve as a novel therapeutic agent for the treatment of neurodegenerative

159 gated a modified UCN2 peptide as a potential therapeutic agent for the treatment of obesity and insul

160 Our results suggest Tinagl1 as a candidate therapeutic agent for TNBC by dual inhibition of integri

161 r ADSCs, and can be developed as a potential therapeutic agent for treating OA.

162 ivated WBCs, LtxA is being investigated as a therapeutic agent for treatment of hematological maligna

163 t S-MGBs have significant potential as novel therapeutic agents for AAT.

164 These findings highlight novel therapeutic agents for AML expressing somatic or germlin

165 re is a growing interest in free radicals as therapeutic agents for antimicrobial applications.

166 , PDE4 inhibitors may be used as efficacious therapeutic agents for asthma in obese and diabetic subj

167 opment of several iP inhibitors as potential therapeutic agents for autoimmune diseases.

168 an attractive approach to identify potential therapeutic agents for cancers and autoimmune diseases.

169 l function may facilitate the development of therapeutic agents for CDD and related disorders.

170 Furans merit consideration as a new class of therapeutic agents for controlling cancer metastasis.

171 reclinical testing of vaccine candidates and therapeutic agents for COVID-19.

172 cules that disrupt N-linked glycosylation as therapeutic agents for diseases such as cancer and viral

173 s can improve the safety and presentation of therapeutic agents for effective immunotherapy, and a hi

174 s, and identify Lsd1 inhibitors as promising therapeutic agents for Gfi1-driven medulloblastoma.

175 ave shown considerable potencies as suitable therapeutic agents for hypertension.

176 of side effects associated with hypothetical therapeutic agents for ischemic stroke that target the i

177 tional opsonizing agents that might serve as therapeutic agents for light chain-associated amyloidosi

178 lar receptor-ligand interactions are used as therapeutic agents for many diseases to inhibit signalli

179 to consistently assess the efficacy of novel therapeutic agents for MS.

180 ates for further optimization as multitarget therapeutic agents for neurodegenerative diseases.

181 overy of tropane alkaloid derivatives as new therapeutic agents for neurological disease and, once sc

182 ase (HDAC), potentially serving as promising therapeutic agents for pancreatic cancer.

183 ied promising leads to be developed as novel therapeutic agents for SCD.

184 ntibodies have become an attractive class of therapeutic agents for solid tumors, mainly because of t

185 in drug development, allowing development of therapeutic agents for targets previously considered und

186 against viral pathogens represent promising therapeutic agents for the control of infection, and the

187 entry, with the potential to be developed as therapeutic agents for the treatment and control of Ebol

188 nd potential of metal complexes as important therapeutic agents for the treatment of cancer.

189 Proteasome inhibitors are established therapeutic agents for the treatment of hematological ca

190 Currently, there are no targeted therapeutic agents for the treatment of this disease, an

191 BET inhibitors are promising therapeutic agents for the treatment of triple-negative

192 at clock modulators hold promise as putative therapeutic agents for this frequent disorder.

193 logical approach for the development of new therapeutic agents for treating autoimmune diseases.

194 ile acids and their derivatives are valuable therapeutic agents for treating these inflammatory metab

195 the framework for the rational design of new therapeutic agents for treatment of ciliopathies and neu

196 bromodomain inhibitors (BBDIs) are candidate therapeutic agents for triple-negative breast cancer (TN

197 Insufficient vaccine doses and the lack of therapeutic agents for yellow fever put global health at

198 the development of flavagline derivatives as therapeutic agents has been hampered because of poor dru

199 The advent of molecularly targeted therapeutic agents has opened a new era in cancer therap

200 loped for anticancer therapies, photodynamic therapeutic agents have a unique profile.

201 Numerous therapeutic agents have been studied under both hypother

202 Several therapeutic agents have been tried for symptomatic relie

203 ead availability and use of modern synthetic therapeutic agents have led to a massive decline in ethn

204 A greater understanding of therapeutic agents impacted by PGx and subsequent implem

205 hallmark features and has potential as a new therapeutic agent in allergic and especially steroid-res

206 of SCFAs, especially butyrate as a promising therapeutic agent in allergic inflammatory diseases.

207 be beneficial as a primary or complementary therapeutic agent in conditions with neutrophilic airway

208 ce of in vivo efficacy of glibenclamide as a therapeutic agent in CS.

209 It represents a potential therapeutic agent in FA.

210 dogs qualify 6 for further development as a therapeutic agent in oncology.

211 hronic exposure after acute injury to either therapeutic agent in the context of reduced renal mass d

212 fection, and as RvD1 has been evaluated as a therapeutic agent in various inflammatory diseases, we e

213 ciated with sensitivity to select classes of therapeutic agents in cell culture.

214 m, and discuss actionable molecular targets, therapeutic agents in clinical translation and known mec

215 We review therapeutic agents in development, designed to disrupt t

216 ent of quinolinone-based mIDH1 inhibitors as therapeutic agents in human trials.

217 ng clinical interventional research on novel therapeutic agents in humans.

218 conomical production of sulfated proteins as therapeutic agents in mammalian systems.

219 t P. pentosaceus-derived MVs hold promise as therapeutic agents in management/treatment of inflammato

220 properties, exosomes are being developed as therapeutic agents in multiple disease models.

221 JAK inhibitors are valuable therapeutic agents in myelofibrosis and show promising r

222 omotes the utility of EVs and their cargo as therapeutic agents in regenerative medicine.

223 omising results and to define the role of MP therapeutic agents in solid organ transplantation.

224 y the invention of recombinant protein-based therapeutic agents in the 1980s.

225 ationale for the use of centrosome-targeting therapeutic agents in treating these cancers.

226 The major categories of therapeutic agents include vasodilators, mesenchymal ste

227 e attempts in the rational design of salient therapeutic agents, including next generation anticancer

228 k-benefit ratio and are necessary to advance therapeutic agents into human trials rapidly and safely

229 The delivery of therapeutic agents into target cells is a challenging ta

230 (NCs) are highly sought after for delivering therapeutic agents into the cell nucleus.

231 made significant progress in delivering new therapeutic agents into the clinic.

232 ntral nervous system, for which no effective therapeutic agent is currently available.

233 One of the hurdles in using CO as a therapeutic agent is the development of pharmaceutically

234 A growing arsenal of therapeutic agents is under development to inhibit this

235 Twenty four out of 30 metabolites plus the therapeutic agent, naproxen (24/30), passed the t-test f

236 ting the development of IL-37 as a potential therapeutic agent of ASD.

237 miriplatin, the uPtDs represent a promising therapeutic agent of the metal-based nanomedicines to re

238 G. mellonella or by direct application as a therapeutic agent on infected larvae.

239 and its defined epitope have potential as a therapeutic agent or target of vaccine design against mu

240 t enables the sustained release of an active therapeutic agent (payload) for targeted delivery to spe

241 In vitro inhibition of neddylation with the therapeutic agent pevonedistat (MLN4924) resulted in a d

242 ion of genotypes, lack of access to specific therapeutic agents, relatively high cost of treatment, a

243 pathogens by controlled chemoattractant and therapeutic agent release.

244 In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not

245 Use of this therapeutic agent should be limited to the context of a

246 animal and clinical studies have examined MP therapeutic agents, some of which have even led to the s

247 f exosomes as selective delivery vehicles of therapeutic agents, such as drugs or hyperthermia-capabl

248 TRT outcomes through combinations with other therapeutic agents; such strategies include administerin

249 TPases provide a strategy that could lead to therapeutic agent targeting oncogenic Ras mutants that a

250 potential lead compounds for development of therapeutic agents targeting aquaporin channel activity.

251 These findings pave the way for therapeutic agents targeting metabolism aimed at reducin

252 oaches have been undertaken in the design of therapeutic agents targeting MMPs for various purposes,

253 n neural circuit function and the actions of therapeutic agents targeting NMDA receptors.

254 for these diseases, but developing effective therapeutic agents targeting the toxic, misfolded protei

255 ms might facilitate the development of novel therapeutic agents targeting these oxidase systems and t

256 data suggest that C-PC may be utilized as a therapeutic agent that can target bone loss mediated by

257 siran is an investigational RNA interference therapeutic agent that inhibits hepatic ALAS1 synthesis.

258 humans with inflammatory bowel disease as a therapeutic agent that modulates inflammation.

259 A therapeutic agent that targets the ECM protease activity

260 roenvironment has impeded the development of therapeutic agents that are effective against metastatic

261 New therapeutic agents that can control not only tumour grow

262 mals may facilitate preclinical screening of therapeutic agents that counter against NAFLD progressio

263 ain therapeutic areas, first-in-class drugs, therapeutic agents that received accelerated approval, a

264 ation is being used to develop effective new therapeutic agents that target ERBB3 in human cancers.

265 with patient outcomes and discuss potential therapeutic agents that target these features.

266 dence on WRN, and support the development of therapeutic agents that target WRN for MSI-associated ca

267 h a US Food and Drug Administration approved therapeutic agent, the small-molecule modulator AMD3100.

268 the potential of SHP2-targeted compounds as therapeutic agents, the growth inhibitory property of SH

269 t DNA pharmacogenetics to identify the ideal therapeutic agent, thereby increasing the probability of

270 We used Doxorubicin as a therapeutic agent, TNFalpha as marker and mediator of an

271 For a blood-borne cancer therapeutic agent to be effective, it must cross the blo

272 opment will guide efforts for use of RA as a therapeutic agent to improve human health.

273 c acid as a candidate molecule to serve as a therapeutic agent to promote remyelination.

274 H(2) S may prove a useful therapeutic agent to protect the human fetal heart again

275 might be regarded as an important supportive therapeutic agent to reduce the early degenerative chang

276 ception to determine the drug's utility as a therapeutic agent to target circuit abnormalities in pat

277 ticle system showed great promise to deliver therapeutic agents to aHSC to treat liver fibrosis.

278 SPMs have potential to serve as targeted therapeutic agents to be used in adjuvant therapy to pro

279 e thus being developed to deliver imaging or therapeutic agents to cancer cells.

280 ing yet could be key for developing rational therapeutic agents to combat infections.

281 nslocate substrate proteins, could be potent therapeutic agents to disassemble toxic protein conforme

282 for BBB dysfunction suggests that targeting therapeutic agents to limit it may be effective across m

283 l axis may further inform the development of therapeutic agents to modulate pro-inflammatory immune r

284 The conjugation of therapeutic agents to polymeric carriers, such as polyet

285 he pathogenesis of HBV infection and develop therapeutic agents to reduce its burden.

286 ty for the selective delivery of imaging and therapeutic agents to solid tumors.

287 elivery of diagnostic biosensing devices and therapeutic agents to the target tissues, organs, or cel

288 ection of small molecules to be developed as therapeutic agents to treat systolic dysfunction.

289 d implicate FAK/Pyk2 inhibitors as potential therapeutic agents to treat vascular inflammatory diseas

290 A novel molecular therapeutic agent was designed and synthesized, which co

291 In this platform trial of therapeutic agents, we randomly assigned hospitalized pa

292 racteristics and mechanisms of action of the therapeutic agents, which are highly challenging to asse

293 treatment, and the exorbitant cost of these therapeutic agents, which limits accessibility for many.

294 tate the design of future tool compounds and therapeutic agents, while their comparison to 5-HT recep

295 nical value of maximising responses by using therapeutic agents with different modes of action, the u

296 ls have been introduced to combine different therapeutic agents with Gd to enhance the efficacy of th

297 strategy for the generation of potent novel therapeutic agents with unique effector functions in can

298 Individual therapeutic agents within each class may have different

299 e insights into the distribution patterns of therapeutic agents within the heart tissue.

300 burden suggests that using an antibody as a therapeutic agent would augment the antiviral immune res